Up­dat­ed: Bridge­Bio inks $100M up­front deal with Ky­owa Kirin for skele­tal dis­or­der drug

Bridge­Bio will pock­et $100 mil­lion as it part­ners with Japan­ese phar­ma Ky­owa Kirin to ex­plore the use of in­fi­gra­tinib in sev­er­al skele­tal dis­or­ders, the com­pa­nies an­nounced Wednes­day morn­ing.

The Cal­i­for­nia biotech is prepar­ing to com­mer­cial­ize its heart pill aco­ramidis, and just a few weeks ago lined up as much as $1.25 bil­lion in fi­nanc­ing.

That Odyssey-of-a-drug, which the FDA will de­cide whether to ap­prove for transthyretin amy­loid car­diomy­opa­thy by the end of No­vem­ber, is not in­volved in the new deal. As­traZeneca al­ready holds the ex­clu­sive li­cense to aco­ramidis in Japan, where the UK drug­mak­er said last Fri­day it plans to ship it off for reg­u­la­to­ry re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER